Myelofibrosis
Conditions
Brief summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Interventions
Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.
DRUGRuxolitinib
Ruxolitinib will be administered per standard of care.
Sponsors
University of Utah
PharmaEssentia
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subject aged ≥ 18 years. * Diagnosed with PMF, post-PV MF, or post-ET MF per WHO 2016 or 2022 criteria, bearing one of these MPN phenotype defining mutations (JAK2, CALR, and MPL), and with a DIPSS score of low, intermediate-1 or intermediate-2. * Subjects must be already on standard of care ruxolitinib per the treating physician for at least 3 months or more, and on a stable dose for at least 6 weeks prior to screening. * Subjects must have spleen volume of \> 450ml by either MRI or CT scan * Subject must have a JAK2, CALR, or MPL allelic burden of ≥20% at screening --Prior treatment for PV or ET with hydroxyurea or ruxolitinib is allowed. If the patient was on pegylated interferon in the past, the progression from PV/ ET to post-PV/ET MF must not have occurred while on pegylated interferon therapy. * ECOG Performance Status ≤ 2. * Adequate organ function as defined as: * Hematologic: * WBC count ≥ 4 x 109/L * Absolute neutrophil count (ANC) ≥1500/mm3 * Platelet count ≥ 75,000/mm3 * Hemoglobin ≥ 8 g/dL * Hepatic: ---Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN) ---AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN * Renal: * Estimated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula * Recovery to baseline or ≤ Grade 1 CTCAE v 6.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator. * Participants must adhere to the following sex and contraceptive/barrier requirements: * If participant is of childbearing potential, they must have a negative pregnancy test * For participants of non-childbearing potential: The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * \< 50 years of age: ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution --≥ 50 years of age: ---Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or ---Had radiation-induced menopause with last menses \>1 year ago; or ---Had chemotherapy-induced menopause with last menses \>1 year ago ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution * Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 6.4.1 and 6.4.3. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
Exclusion criteria
* PV or ET patients who progressed while on pegylated interferon or ropeginterferon therapy. * Receiving other investigational agents. * Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt (Patients with pre-existing depression who are well-controlled and on stable doses of antidepressants are eligible). * Evidence of severe retinopathy or clinically significant eye disease. * History or presence of active serious or untreated autoimmune disease. * History of solid organ transplant. * Liver cirrhosis Child-Pugh score B or C. -≥ 5% blasts in peripheral blood or bone marrow. * Prior systemic anti-cancer therapy or any investigational therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter. * Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery. * The diagnosis of another malignancy which, in the investigator's opinion, is likely to significantly impact study participation. * Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions: * Cardiovascular disorders: * Uncontrolled hypertension, in the opinion of the investigator * Congestive heart failure New York Heart Association Class II or greater, unstable angina pectoris, serious cardiac arrhythmias. * Stroke or myocardial infarction within the past 3 months * Significant coronary stenosis, in the opinion of the investigator * QTc prolongation defined as a QTcF \> 500 ms. * Known congenital long QT. * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, \[subjects may not receive the drug through a feeding tube\], social/ psychological issues, etc.) * Known HIV infection with a detectable viral load within 6 months of the anticipated start of treatment. Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial. -Active infection requiring systemic therapy, including, but not limited to: tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. * Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give informed consent, comply with the study protocol or complete the study. * Known prior severe hypersensitivity to investigational product (IP) or any component in its formulations (NCI CTCAE v 6.0 Grade ≥ 3). * Subjects taking prohibited medications as described in Section 7.8. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0). | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
| The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment. | 2 years | To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of subjects who achieve >50% reduction in JAK2 V617F mutation burden. | 2 years | To assess the incidence of patients who achieve \>50% reduction in JAK2 V617F mutation burden. |
| Change in JAK2, CALR, MPL mutations allelic burden. | 2 years | To assess the rate of reduction of JAK2, CALR, MPL mutations allelic burden. |
| The proportion of subjects who achieve a 25% decrease in spleen volume by 24 weeks from initiation of combination treatment. | 24 weeks | To assess the rate of 25% spleen volume reduction at 24 weeks of the combination (Abdominal MRI will be done for spleen size measurement). |
| Change in quality of life Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) from baseline and throughout treatment. | 2 years | To assess the change in the quality of life MPN-SAF TSS score. The MPN-SAF questionnaire consists of 10 questions asking patients to rate their symptoms on a scale of 1 to 10, with 0 being no symptoms and 10 being the worst symptoms. |
| The proportion of subjects who progress to blastic phase and secondary acute myeloid leukemia at 2 years post-treatment. | 2 years | To assess the rate of blastic transformation. |
| The proportion of subjects who have a change in bone marrow fibrosis grade. | 2 years | To assess the rate of change in myelofibrosis (MF) grade (MF grade 0 to 3, the higher the worse). |
Countries
United States
Contacts
CONTACTNicole Fisher
CONTACTTsewang Tashi, MD
Outcome results
None listed